Which is better, epitalon or thymalin?
Neither has evidence to support clinical use. Epitalon is covered by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), which is not binding and does not change its evidence grade; thymalin has no US compounding route. Epitalon is a synthetic, defined tetrapeptide, whereas thymalin is a bovine tissue extract of undefined composition with no US nomination. Thymalin's evidence edge (human RCT versus human observational) rests on one sparsely reported randomized, placebo controlled trial from the developing institute that has never been independently replicated. The same 2003 trial is often cited for epitalon, but its other arm tested the pineal extract Epithalamin, not synthetic epitalon. [2] [3] [6] [7] [8] [12]
How do epitalon and thymalin compare?
| Dimension | Epitalon | Thymalin |
|---|---|---|
| Evidence grade [1] [2] [3] [6] [10] [11] | Human observational. Two Russian studies reported higher melatonin output after the peptide, but their abstracts do not state design or sample size. Telomere and life span data come from human cell lines and a lifelong mouse study; the randomized trial often cited used the pineal extract Epithalamin, not synthetic epitalon. | Human RCT. One sparsely reported randomized, placebo controlled trial in elderly people from the developing institute, never independently replicated, plus a COVID-19 report whose abstract does not state the sample size or how patients were assigned. |
| Note: Both grades rest largely on work from the developing institute. | ||
| What it is [1] [5] | A synthetic tetrapeptide (Ala-Glu-Asp-Gly) with a defined structure, modeled on a bovine pineal extract. | A mixture of low molecular weight peptides extracted from calf thymus, registered as a drug in Russia. |
| Note: A defined molecule can be tested for identity and purity; an extract of undefined composition cannot be fully characterized. | ||
| Proposed mechanism [1] [4] [5] | Induces telomerase (hTERT) expression and lengthens telomeres in human cell lines; proposed effects on gene expression and melatonin rhythm. | Short thymic peptides proposed to promote T lymphocyte maturation; activated hematopoietic stem cell differentiation in culture. |
| Main claimed use [2] [3] [6] | Aging and longevity: in female SHR mice it extended life span of the longest lived 10% and reduced spontaneous tumors, without changing mean life span. | Immune support: reported fewer infections in elderly patients and faster normalization of inflammatory markers in hospitalized COVID-19 patients. |
| Safety concerns [2] [3] | No systematic human safety data; theoretical concern that telomerase activation could support existing tumors, although mice had fewer tumors. | No systematic safety data; allergy to bovine protein and theoretical prion or adventitious agent risk from unverified thymus products. |
| FDA and compounding status [7] [8] [12] [13] | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection in intermittent courses) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). | Not FDA approved and not identified on any 503A nomination list or PCAC agenda; as an undefined tissue extract it is not a 503A bulk candidate, and HHS's October 2026 draft policy does not cover it. |
| WADA status [9] | Prohibited at all times under S0 (non-approved substances). | Unclear; not named on the list. Athletes should confirm with their anti-doping organization. |
| Access and cost [7] [8] [12] | Only as a single-ingredient compounded product on a patient-specific prescription under HHS's October 28, 2026 draft enforcement discretion policy, if its conditions are met; it is not on the 503A bulks list. No verified compounded price yet. | No lawful US channel. Prescription drug in Russia and some neighboring countries only. |
| Human dosing data [2] [3] | Not established. Mouse studies used 0.1 ug per mouse in monthly courses; Russian human reports used 10 mg intramuscular courses of the extract Epithalamin. | Not established in indexed literature; Russian labeling describes intramuscular courses with no published dose finding trial. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Epitalon | Thymalin |
|---|---|---|
| Class | Synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on the bovine pineal extract Epithalamin | Polypeptide extract from calf thymus (a mixture of low molecular weight peptides), registered as a drug in Russia |
| What it is | 4 amino acid peptide from a pineal gland extract: telomere and lifespan data in cells and mice, human melatonin studies of unstated design, not FDA approved. | Russian calf thymus peptide extract used to adjust immunity; one sparsely reported randomized trial from its developer, never replicated; no FDA review. |
| Evidence | Evidence: Human observational evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: HHS interim policy (draft) | Regulatory: Unscheduled |
| Compounding | Epitalon is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026 for insomnia: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds epitalon when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection, in intermittent courses), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add epitalon to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. | Thymalin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. As an animal tissue extract of undefined composition it is not a candidate for 503A bulk compounding, and it is not eligible for 503B outsourcing. It is registered as a prescription drug in Russia and some neighboring countries. Products sold in the United States under this name for human use are unapproved drugs. |
| WADA | WADA: WADA prohibited | WADA: WADA status unclear |
| Routes | Subcutaneous injection (as sold), Intramuscular injection (Russian Epithalamin reports), Intranasal and oral products exist without absorption data | Intramuscular injection (Russian labeling and reports), Subcutaneous injection (as sold) |
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has epitalon been tested directly against thymalin?
No published trial has compared epitalon and thymalin directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do epitalon and thymalin cost?
| Dimension | Epitalon | Thymalin |
|---|---|---|
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Price detail | Epitalon price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Epitalon page and the Thymalin page.
Frequently asked questions
Is there any study comparing epitalon and thymalin directly?
No study compares synthetic epitalon with thymalin. The 2003 Khavinson and Morozov trial, which its paper describes as randomized and placebo controlled, assigned elderly people to placebo, Thymalin, or the pineal extract Epithalamin, but it is sparsely reported, came from the developing institute, has never been independently replicated, and used the extract rather than synthetic epitalon. [3]
Can I get either one legally in the United States?
Epitalon possibly, under conditions; thymalin, no. Epitalon is not FDA approved or on the 503A bulks list, but it is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection in intermittent courses) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Thymalin is not covered and has no lawful US route. State law still applies. [7] [8] [12] [13]
Does epitalon lengthen telomeres in people?
That has not been shown. Telomerase activation and telomere elongation were documented in cultured human cell lines, and the lifespan data come from mice. No human study has measured telomere length after synthetic epitalon. [1] [2] [4]
Does thymalin boost the immune system?
The developer's 2003 trial, described as randomized and placebo controlled, reported a lower incidence of acute respiratory disease in elderly people, a later report described faster normalization of inflammatory markers in COVID-19 patients, and a cell study showed stem cell differentiation. The trial is sparsely reported, and none of this has been independently replicated. [3] [5] [6]
Are they banned in sport?
Epitalon is prohibited at all times under WADA section S0 as a non-approved substance. Thymalin is not named on the list, so its status is unclear; tested athletes should check with their anti-doping organization before using any unapproved peptide. [9]
Conditions studied
From the blog
- Epitalon human studies: what the small cohorts actually measured
Most epitalon human data come from one group and used the pineal extract Epithalamin, not synthetic epitalon. What each study measured, the claimed benefits versus the evidence, and side effects.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003PubMed 12937682, 2003
- [2]Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003PubMed 14501183, 2003
- [3]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003PubMed 14523363, 2003
- [4]Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025PubMed 40908429, 2025
- [5]Khavinson VK et al. Thymalin: activation of differentiation of human hematopoietic stem cells. Bull Exp Biol Med 2020PubMed 33237528, 2020
- [6]Khavinson VK et al. Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19. Stem Cell Rev Rep 2021PubMed 33575961, 2021
- [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [8]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA
- [9]WADA Prohibited List, section S0 non-approved substancesWADA
- [10]Korkushko OV et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol 2007PubMed 17969590, 2007
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Epitalon vs thymalin: evidence, cost, and legality. https://peptideagent.ai/compare/epitalon-vs-thymalin- HTML link
<a href="https://peptideagent.ai/compare/epitalon-vs-thymalin">Epitalon vs thymalin: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.